Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe
Laurence Torcel‐Pagnon(Sanofi (France)), Xavier Kurz(European Medicines Agency), Myint Tin Tin Htar(Pfizer (France)), Anne Charrat(Sanofi (France)), Patrick Mahy(Sciensano (Belgium)), Marianne A. B. van der Sande(National Institute for Public Health and the Environment), Tyra Grove Krause(Statens Serum Institut), François Simondon(Délégation Paris 5), Cédric Mahé(Sanofi (France)), Vincent Bauchau(UCB Pharma (Belgium))
Cited by 22
Related Papers
Bulletin of the World Health Organization
|Bulletin of the World Health Organization|2001|7.2k
The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis
|PLoS Pathogens|2008|504
Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort
|International Journal of Epidemiology|2020|280
Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
|Eurosurveillance|2020|238
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study
|The Lancet Infectious Diseases|2022|218